Table 5.
Therapeutic options recommended in retherapy of HCV infections (alphabetically)
| Genotype | Ineffective therapy | Proposed retherapy |
|---|---|---|
| 1 | BOC + PegIFN + RBV PegIFN + RBV SMV + PegIFN + RBV TVR + PegIFN + RBV |
GZR/EBR ± RBV SOF/LDV ± RBV OBV/PTV/r + DSV ± RBV VEL/SOF |
| ASV + DCV GZR/EBR ± RBV LDV/SOF ± RBV OBV/PTV/r + DSV ± RBV VEL/SOF |
F0-F3: more effective proposed therapies are awaited F4: SOF + GZR/EBR + RBV SOF + OBV/PTV/r + DSV ± RBV SOF + SMV + DCV + RBV |
|
| 2 | PegIFN + RBV | SOF + RBV |
| SOF + RBV | VEL/SOF | |
| 3 | PegIFN + RBV | SOF + PegIFN + RBV SOF + RBV |
| SOF + PegIFN + RBV SOF + RBV |
VEL/SOF | |
| SOF + DCV + RBV | F0-F3: more effective proposed therapies are awaited F4: VEL/SOF |
|
| 4 | PegIFN + RBV SOF + PegIFN + RBV SOF + RBV |
GZR/EBR ± RBV LDV/SOF ± RBV OBV/PTV/r + RBV VEL/SOF |
| GZR/EBR ± RBV LDV/SOF ± RBV OBV/PTV/r + RBV VEL/SOF |
F0-F3: more effective proposed therapies are awaited F4: SOF + GZR/EBR + RBV SOF + OBV/PTV/r + DSV + RBV SOF + SMV + DCV + RBV |
|
| 5, 6 | PegIFN + RBV | VEL/SOF |
| SOF + PegIFN + RBV | ||
| SOF + RBV |